Chemoradiation, Consolidation Chemotherapy, and Watch and Wait for Early Rectal Cancer.

Autor: Cerdan-Santacruz C; Colorectal Surgery Department, Hospital Universitario de la Princesa, Madrid, Spain., São Julião GP; Division of Colorectal Surgery, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Vailati BB; Division of Colorectal Surgery, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil., Perez RO; Division of Colorectal Surgery, Hospital Alemão Oswaldo Cruz, São Paulo, Brazil.; Department of Surgical Oncology, Hospital Beneficencia Portuguesa, São Paulo, Brazil.
Jazyk: angličtina
Zdroj: Clinics in colon and rectal surgery [Clin Colon Rectal Surg] 2023 Aug 11; Vol. 37 (4), pp. 216-221. Date of Electronic Publication: 2023 Aug 11 (Print Publication: 2024).
DOI: 10.1055/s-0043-1770710
Abstrakt: As watch and wait has become an attractive management alternative among patients with rectal cancer who achieve a clinical complete response to neoadjuvant chemoradiation, the focus of organ preservation has now shifted toward the use of this approach in patients with early rectal cancer. These patients would otherwise be treated without the use of neoadjuvant therapy for oncological reasons. The sole purpose of any neoadjuvant treatment here would be the achievement of a complete clinical response in an attempt to avoid total mesorectal excision. This has become particularly interesting after the incorporation of total neoadjuvant therapy regimens. These regimens have resulted in significantly higher rates of complete tumor regression and therefore become an interesting alternative among early rectal cancer patients where organ preservation is desired. The present review provides an overview of the currently available evidence and the preliminary experience with this rather controversial approach.
Competing Interests: Conflict of Interest B.B.V., G.P.S.J., and R.O.P. have received honoraria from Johnson & Johnson not associated with the present study.
(Thieme. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: